Yahoo · Nov 12, 2026
Moleculin Secures Australian Patent for Annamycin Formulation Technology
Patent strengthens intellectual property protection for preparation of preliposomal Annamycin lyophilizate HOUSTON, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”) today announced the grant of an Australian patent covering the preparation of preliposomal Annamycin lyophilizate, strengthening the Company’s intellectual property protection for a key aspect of Annamycin’s formulation technology. Australian Patent No. 2020303572 was granted to

